Archives: Agenda

Value by Design: Strategic Execution Architecture in Clinical-Stage Biotech

Running four Phase II oncology studies in parallel exposed a fundamental truth: in clinical-stage biotech, execution failure is not a delivery problem — it is a value problem. This session draws on Ryvu’s experience building an internal clinical execution unit from scratch, covering the strategic decisions behind insourcing key functions, building a CEE-anchored site network, and delivering ASH 2025 data on time. Attendees will leave with a practical framework for thinking about clinical program architecture as a value inflection decision, not an operational one.

Industry trends impacting 2026 and beyond for leaders in financial services overseeing use of AI

As financial institutions move from experimentation to enterprise-wide deployment, the AI agenda is becoming more complex and more consequential. We examine the key trends shaping how AI is being adopted, governed and scaled across financial services, from the rise of agentic systems and evolving regulatory expectations, to the growing pressure to demonstrate real commercial value. Drawing on GlobalData’s latest research, we explore how leading firms are prioritising investment, where momentum is building, and where risks are emerging. This session provides a clear view of what leaders need to focus on now to stay competitive, compliant and credible as AI matures.

END OF DAY 1 AND NETWORKING DRINKS

Best 3 LinkedIn posts from day 1 with hashtag #CTO and @Clinical Trials in Oncology Event Series tagged will win a prize in day 2 morning’s prize draw during chair’s opening remarks. Deadline end of drinks reception day 1. You must be present to win!